Search This Blog

Friday, August 2, 2019

Stemline up 3% premarket on Q2 beat

Stemline Therapeutics (STML) Q2 results: Elzonris sales: $13M.
Net Loss: ($16.8M) (+11.1%); Loss Per Share: ($0.42) (+36.4%); Quick Assets: $103.9M (+72.9%).
Shares are up 3% premarket.
Previously: Stemline Therapeutics EPS beats by $0.14, beats on revenue(Aug. 2)
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)